Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Generation Bio Co. stock logo
GBIO
Generation Bio
$5.34
$5.48
$3.00
▼
$6.95
$35.99M2.05160,744 shsN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$2.05
-5.5%
$3.24
$1.32
▼
$5.08
$138.68M1.331.10 million shs572,902 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$6.48
+0.8%
$8.40
$6.36
▼
$16.77
$138.71MN/A229,349 shs352,108 shs
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
$3.07
-1.6%
$4.75
$2.99
▼
$54.97
$141.13M1.23855,090 shs550,734 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Generation Bio Co. stock logo
GBIO
Generation Bio
0.00%0.00%0.00%0.00%-1.11%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-5.53%-15.29%-36.92%-50.78%+35.76%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+0.78%-21.26%-15.51%-52.74%-90.83%
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
-1.60%-17.03%-21.08%-50.88%-92.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Generation Bio Co. stock logo
GBIO
Generation Bio
$5.34
$5.48
$3.00
▼
$6.95
$35.99M2.05160,744 shsN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$2.05
-5.5%
$3.24
$1.32
▼
$5.08
$138.68M1.331.10 million shs572,902 shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$6.48
+0.8%
$8.40
$6.36
▼
$16.77
$138.71MN/A229,349 shs352,108 shs
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
$3.07
-1.6%
$4.75
$2.99
▼
$54.97
$141.13M1.23855,090 shs550,734 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Generation Bio Co. stock logo
GBIO
Generation Bio
0.00%0.00%0.00%0.00%-1.11%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-5.53%-15.29%-36.92%-50.78%+35.76%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+0.78%-21.26%-15.51%-52.74%-90.83%
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
-1.60%-17.03%-21.08%-50.88%-92.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Generation Bio Co. stock logo
GBIO
Generation Bio
2.00
Hold$5.25-1.69% Downside
MacroGenics, Inc. stock logo
MGNX
MacroGenics
2.40
Hold$8.50314.63% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.63
Moderate Buy$33.00409.26% Upside
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
2.00
Hold$42.331,278.94% Upside

Current Analyst Ratings Breakdown

Latest GBIO, SION, RNA, and MGNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
UpgradeSell (E) ➝ Sell (E+)
11/3/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Reiterated RatingSell (D-)
11/3/2026
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
Reiterated RatingSell (D-)
10/28/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Lower Price TargetBuy$25.00 ➝ $20.00
10/23/2026
MacroGenics, Inc. stock logo
MGNX
MacroGenics
Initiated CoverageMarket Perform ➝ Positive
10/22/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Initiated CoverageBuy$15.00
9/15/2026
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
Boost Price TargetNeutral$5.00 ➝ $6.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Generation Bio Co. stock logo
GBIO
Generation Bio
$19.89M1.81N/AN/A$12.91 per share0.41
MacroGenics, Inc. stock logo
MGNX
MacroGenics
$149.50M0.88N/AN/A$0.39 per share5.26
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/A$9.50 per shareN/A
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/AN/AN/AN/A$5.32 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Generation Bio Co. stock logo
GBIO
Generation Bio
-$131.67M-$9.34N/AN/AN/A-410.13%-94.82%-34.13%N/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
-$74.62M-$0.81N/AN/AN/A-45.37%-246.62%-31.36%N/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A-$2.15N/AN/AN/AN/AN/AN/AN/A
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
-$75.27M-$2.44N/AN/AN/AN/A-39.78%-37.21%N/A

Latest GBIO, SION, RNA, and MGNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$0.8109-$0.25+$0.5609-$1.2020$15.00 million$15.32 million
11/10/2026Q3 2026
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
-$0.62-$0.72-$0.10-$0.72N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Generation Bio Co. stock logo
GBIO
Generation Bio
N/AN/AN/AN/AN/A
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Generation Bio Co. stock logo
GBIO
Generation Bio
N/A
4.44
4.44
MacroGenics, Inc. stock logo
MGNX
MacroGenics
N/A
2.75
2.75
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
10.46
10.46
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/A
13.92
13.92

Institutional Ownership

CompanyInstitutional Ownership
Generation Bio Co. stock logo
GBIO
Generation Bio
95.22%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
96.89%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Generation Bio Co. stock logo
GBIO
Generation Bio
21.10%
MacroGenics, Inc. stock logo
MGNX
MacroGenics
13.60%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Generation Bio Co. stock logo
GBIO
Generation Bio
1506.74 million5.32 millionOptionable
MacroGenics, Inc. stock logo
MGNX
MacroGenics
29363.91 million55.04 millionOptionable
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
19021.57 millionN/AOptionable
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
5945.24 million42.93 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Generation Bio stock logo

Generation Bio NASDAQ:GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

MacroGenics stock logo

MacroGenics NASDAQ:MGNX

$2.05 -0.12 (-5.53%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.05 0.00 (0.00%)
As of 11/17/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$6.48 +0.05 (+0.78%)
As of 11/17/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Sionna Therapeutics stock logo

Sionna Therapeutics NASDAQ:SION

$3.07 -0.05 (-1.60%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$3.12 +0.05 (+1.56%)
As of 11/17/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”). Despite having long been identified as a critical component for proper CFTR function, NBD1 has been considered “undruggable,” and none of the currently approved CF therapies directly stabilizes NBD1. Worldwide revenue for approved CFTR modulators was approximately $10 billion in 2023 and is expected to grow to $15 billion by 2029. Leveraging more than a decade of our co-founders’ research on NBD1, we are advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in the NBD1 domain. Approximately 90% of people with CF carry at least one copy of the F508del genetic mutation. We believe stabilizing NBD1 is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients. We have employed biophysical, cell-based and virtual screening campaigns and extensive use of structural biology to guide the optimization of novel small molecule NBD1 stabilizers. We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (“PK”) profile of single and multiple ascending doses in healthy subjects. These trials are randomized (3:1 active:placebo), doubled-blinded, placebo-controlled and are being conducted in Australia. As of January 14, 2025, five single ascending dose (“SAD”) cohorts and three multiple ascending dose (“MAD”) cohorts of SION-719 have been completed, with over 60 healthy subjects dosed, and six SAD cohorts and three MAD cohorts of SION-451 have been completed, with over 70 healthy subjects dosed. Both SION-719 and SION-451 have been generally well tolerated based on interim Phase 1 clinical data as of the data cutoff date of January 14, 2025. We have established target exposure levels for SION-719 and SION-451 to potentially provide clinically meaningful benefit, if administered as part of a dual combination or as an add-on to the current standard of care (“SOC”), based on our preclinical cystic fibrosis human bronchial epithelial (“CFHBE”) model. In these trials, we have achieved the target concentrations for SION-719 and SION-451 with single and multiple doses. We plan to continue enrolling healthy subjects in additional MAD cohorts. We are also developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models. In July 2024, we in-licensed three clinical-stage compounds from AbbVie Global Enterprises Ltd. (“AbbVie”) to expand our portfolio of combination product opportunities, including galicaftor (SION-2222), which targets CFTR’s transmembrane domain 1 (“TMD1”), and has completed Phase 2 clinical trials. In addition, we recently completed a Phase 1 clinical trial evaluating SION-109, which targets CFTR’s intracellular loop 4 (“ICL4”) region. We plan to evaluate multiple NBD1 stabilizer candidates and complementary modulator candidates and select the most promising candidates to advance into later-stage development. Initially, we intend to evaluate the lead NBD1 stabilizer candidate in combination with the current standard of care, Trikafta, in a proof-of-concept trial. In parallel, we will determine the proprietary dual combination that we believe is optimal to advance into a later-stage clinical trial in CF patients. We were incorporated under the laws of the State of Delaware in August 2019 under the name Sling Therapeutics, Inc., and changed our name to Sionna Therapeutics, Inc. in July 2021. Our principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA. We have one subsidiary, Sionna Therapeutics Securities Corporation (f/k/a Sling Therapeutics Securities Corporation), formed in 2020 under the laws of the Commonwealth of Massachusetts.